

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

**CHANGE OF JOINT COMPANY SECRETARY AND PROCESS AGENT
AND
WAIVER FROM STRICT COMPLIANCE WITH
RULES 3.28 AND 8.17 OF THE LISTING RULES**

The board (the “**Board**”) of directors (the “**Directors**”) of Keymed Biosciences Inc. (the “**Company**”) hereby announces that Mr. Keith Shing Cheung WONG (“**Mr. WONG**”) has tendered his resignation as (i) the joint company secretary of the Company (the “**Joint Company Secretary**”); and (ii) the authorized representative of the Company for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from March 29, 2022.

Mr. WONG has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company.

The Board is pleased to further announce that Ms. Vivien Pak Yu TAM (“**Ms. TAM**”) has been appointed as one of the Joint Company Secretaries and Process Agent with effect from March 29, 2022. Mr. Yanrong ZHANG (“**Mr. ZHANG**”) will continue to serve as the other Joint Company Secretary.

The biographical details of Mr. ZHANG and Ms. TAM are set out below:

Mr. ZHANG has been the chief financial officer of the Company since September 2020, and is responsible for overall management of financial, fundraising and business development. He is also a vice president of Keymed Bioscience (Chengdu) Co., Ltd. (康諾亞生物醫藥科技(成都)有限公司). From July 2012 to September 2020, he worked at the investment banking department of China International Capital Corporation (中金公司), with his last position as vice president. Mr. ZHANG graduated with a bachelor’s degree in business administration from Shandong University (山東大學) in the PRC in July 2009. He then obtained his master’s degree from the University of Sheffield in the United Kingdom in January 2011.

Ms. TAM serves as an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited (方圓企業服務集團(香港)有限公司), a professional services provider specializing in corporate services, and has over six years of experience in corporate secretarial field. Ms. TAM has been admitted as an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute of the United Kingdom in 2018. Ms. TAM obtained a bachelor's degree in China Studies from Hong Kong Baptist University in 2014 and a master's degree in Professional Accounting and Corporate Governance from City University of Hong Kong in 2017.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the appointment of Mr. ZHANG as one of the Joint Company Secretaries and the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) in relation to the eligibility of Mr. ZHANG to act as the Joint Company Secretary for a period of three years from the date of the Company's listing (i.e. July 8, 2021) to July 7, 2024 (the “**Waiver Period**”), on the condition that Mr. WONG, who meets the requirements under Rules 3.28 and 8.17 of the Listing Rules, is engaged as the Joint Company Secretary and provides assistance to Mr. ZHANG to acquire the “relevant experience” within the meaning of Rule 3.28 of the Listing Rules and to discharge his duties as the Joint Company Secretary during the Waiver Period. The Waiver will be revoked immediately when Mr. WONG, during the Waiver Period, ceases to provide assistance to Mr. ZHANG.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to a new waiver (the “**New Waiver**”) to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period from the date of appointment of Ms. TAM as the Joint Company Secretary (i.e. from March 29, 2022) to July 7, 2024 (i.e. the remaining period of the Waiver Period) (the “**New Waiver Period**”) in relation to the eligibility of Mr. ZHANG to act as a Joint Company Secretary. The New Waiver is granted on the conditions that:

- (i) Mr. ZHANG will be assisted by Ms. TAM during the New Waiver Period;
- (ii) this waiver could be revoked if there are material breaches of the Listing Rules by the Company; and
- (iii) the Company will announce the reasons for, and the details and conditions of the New Waiver, and the qualification and experience of both Mr. ZHANG and Ms. TAM.

The publication of this announcement aims to satisfy condition (iii) set out above.

Before the end of the New Waiver Period, the Company must demonstrate and seek the Stock Exchange's confirmation that Mr. ZHANG, having had the benefit of Ms. TAM's assistance during the New Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The New Waiver applied to Ms. TAM's appointment as the Joint Company Secretary only. The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its gratitude to Mr. WONG for his valuable contribution to the Company during his tenure of service, and to welcome Ms. TAM on her new appointment.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, March 29, 2022

As at the date of this announcement, the Board comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive directors.